Absci Corporation · NASDAQ:ABSI

Absci — 2025 J.P. Morgan Healthcare Conference

24 slides from Absci's conference presentation, Jan 15, 2025

  1. Slide 1: Generative AI Drug Creation - 2025 J.P. Morgan Healthcare Conference

    GENERATIVE AI ABSCI CORPORATION 2025 ALL RIGHTS RESERVED DRUG CREATION 2025 J.P. MORGAN HEALTHCARE CONFERENCE

  2. Slide 2: Disclaimers: Forward-Looking Statements

    2C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Disclaimers Forward-Looking Statements Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 19

  3. Slide 3: Absci is a data-first generative AI Drug Creation company

    3C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Absci is a data-first generative AI Drug Creation™ company P A R T N E R S H I P S Strategic Collaboration with AMD committing $20M equity investment in Absci Achieved 2024 partnership guidance with 4

  4. Slide 4: Ingredients for Success: Leadership in AI de novo antibody design

    4C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . LEADING AI MODELS Leading de novo AI model for antibody design with proof- points in internal and partnered programs DATA ADVANTAGE Proprietary ultra-high throughput data generation in 77,000+ ft2 lab

  5. Slide 5: Amassing high-quality data at scale for AI model training and validation

    5C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Since 2020 Absci has been amassing high-quality data at scale for AI model training and validation D ata A dvantage Leading A I M odels “M ultilingual” Expertise C om pute A t Scale DATA TO TRAIN Propr

  6. Slide 6: Leadership in AI de novo design of antibody-based therapeutics

    6C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Leadership in AI de novo design of antibody-based therapeutics EVQLSEVGA . . . de novo antibody design model creates epitope-specific binders given a target structure Designed in framework of choice or

  7. Slide 7: Leading AI models to create novel & differentiated therapeutics

    7C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Leading AI models to create novel & differentiated therapeutics “Smart” biologics Enhanced Potency & MOA Engineer selectivity, minimizing off target toxicity Agonism vs. Antagonism Bind Specific extrac

  8. Slide 8: Platform Case Studies

    8C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Platform Case Studies AI LEAD OPTIMIZATIONDE NOVO ANTIBODY DESIGN Goal: create universally neutralizing HIV antibody by binding conserved epitope within “caldera” region of HIV gp120 Absci’s de novo de

  9. Slide 9: De novo model progress 2022-2025

    9C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . de novo Model v1 Absci was the first to design and validate novel antibodies using zero-shot generative AI in BioRxiv preprint de novo Model v2 Demonstrated de novo design model’s broad applicability t

  10. Slide 10: Strategic Collaboration to Accelerate the Future of AI Drug Discovery

    10C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Strategic Collaboration to Accelerate the Future of AI Drug Discovery x

  11. Slide 11: 11C R V E D .

    11C O P Y R I G H T © 2 0 2 4 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D .

  12. Slide 12: Why We Chose AMD: Key Advantages of AMD MI300X Chips

    12C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Why We Chose AMD: Key Advantages of AMD MI300X Chips D ata A dvantage Leading A I M odels D rug D iscovery Expertise C om pute A t Scale Unmatched Training Resolution • Why it matters: Model large pro

  13. Slide 13: AI Drug Creation Partnerships

    13C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . AI Drug Creation™ Partnerships Data & compute collaborations 25+ PARTNERED PROGRAMS SCALING COMPUTE 4 NAMED INTERNAL PROGRAMS ADDITIONAL PROGRAMS IN EARLY DEVELOPMENT IMPROVING MODELS INCREASING EFFIC

  14. Slide 14: Multilingual team with expertise in AI and drug creation

    14C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ”Multilingual” team with expertise in AI and drug creation Sean McClain Founder, CEO & Director Andreas Busch, PHD Chief Innovation Officer Zach Jonasson, PHD Chief Financial Officer & Chief Business

  15. Slide 15: Advancing and expanding our pipeline of novel assets designed using AI

    15C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . INFL. Bowel Disease / TL1A Androgenic Alopecia / PRLR Immuno-oncology / Undisclosed 3 New Early Discovery Programs Target Lead ID Candidate ID IND-Enabling ABS-101 ABS-201 ABS-301 Phase 1 Oncology / H

  16. Slide 16: Latest NHP data confirm compelling profile and target engagement

    16C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Latest NHP data confirm compelling profile and target engagement Confirmatory target engagement N o n - H u m a n P r i ma t e s ( N H P ) s i n gl e d o s e P K / P D s t u d y h i g h l i g h t s :

  17. Slide 17: ABS-201 potential to unlock a new category of therapy in hair re-growth

    17C O P Y R I G H T © 2 0 2 4 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 has the potential to unlock a wholly new category of therapy in hair “re-growth” Significant unmet clinical need for androgenic alopecia Large market: 80-90M patients in U.S., which is a highl

  18. Slide 18: Significant underserved patient population looking for therapeutic innovation

    18C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Significant underserved patient population looking for therapeutic innovation FEMALE ANDROGENIC ALOPECIA ~30M women in U.S. Only 1 FDA approved therapy for women ~50M men in the U.S. Only 2 FDA approv

  19. Slide 19: Prolactin Receptor inhibition is an innovative alternative

    19C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Prolactin Receptor inhibition is an innovative alternative to current treatment options Proposed impact of ABS-201 on Hair Cycle Stages ABS-201 has the potential to: Catagen ↑↑ Apoptosis & Regression

  20. Slide 20: Anti-PRLR mAb promotes and sustains long-term hair growth in NHP

    20C O P Y R I G H T © 2 0 2 4 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Treatment with an anti-PRLR mAb promotes and sustains long-term hair growth in NHP TOP HEAD VIEW OF STUMPTAILED MACAQUE’S SHOWING PHENOTYPIC CHANGE OVER TIME 40mg/kg s.c. Q2W for 28 weeks Disclosure f

  21. Slide 21: ABS-201 shows superior efficacy vs 5% topical minoxidil

    21C O P Y R I G H T © 2 0 2 4 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 shows superior efficacy vs 5% topical minoxidil in 21d hair regrowth model Administration: mAbs i.p. biweekly; Minoxidil topical daily Untreated (n=11) Isotype (n=11) Minoxidil 5% (n=11) ABS-2

  22. Slide 22: ABS-201 represents a significant untapped new market opportunity

    22C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 represents a significant untapped new market opportunity Consumers across income levels invest in aesthetic treatments, driving steady demand. STRONG WILLINGNESS TO SELF-PAY ACROSS DEMOGRAPHIC

  23. Slide 23: Leading AI platform driving numerous near-term value inflection points

    23C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . 1H 2025 2H 20251H 2025 Leading AI platform driving numerous near-term value inflection points ABS-101 Ph 1 double-blind, placebo-controlled Clinical Trial initiation ABS-101 Phase 1 Interim Data Reado

  24. Slide 24: Best in class generative AI platform, asset portfolio, partnerships

    24C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . B E S T I N C L A S S G E N E R A T I V E A I P L A T F O R M H I G H - V A L U E A S S E T P O R T F O L I O W I N - W I N P A R T N E R S H I P S

Absci — 2025 J.P. Morgan Healthcare Conference on 6ix